譜系細胞療法有限公司
US ˙ NYSEAM ˙ US53566P1093

SecurityLCTX / Lineage Cell Therapeutics, Inc.
InstitutionBlackRock, Inc.
Latest Disclosed Ownership2,234,545 shares
Ownership 1.00%
BlackRock, Inc. ownership in LCTX / Lineage Cell Therapeutics, Inc.

2025-07-17 - BlackRock, Inc. has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,234,545 shares of Lineage Cell Therapeutics, Inc. (US:LCTX). This represents 1.0 percent ownership of the company. In their previous filing dated 2025-04-24 , BlackRock, Inc. had reported owning 11,453,305 shares, indicating a decrease of -80.49 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2025-07-17 2025-07-17 13G/A 11,453,305 2,234,545 -80.49 1.00 -80.00
2025-04-24 2025-04-24 13G 10,094,677 11,453,305 13.46 5.00 8.70
2025-02-05 2025-02-05 13G/A 9,919,800 10,094,677 1.76 4.60 -13.21
2024-11-08 2024-11-08 13G 9,919,800 9,919,800 0.00 5.30 0.00
2024-10-22 2024-10-22 13G 9,919,800 5.30
2022-07-08 2022-07-08 13G 10,008,510 3,755,757 -62.47 2.20 -62.71
2022-02-04 2022-02-04 13G 10,008,510 5.90

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 3,864,757 30,644 0.80 6,106 -4.62 0.0001
2026-02-12 2025-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 3,834,113 1,603,357 71.88 6,403 69.86 0.0001
2025-11-12 2025-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 2,230,756 -29,992 -1.33 3,770 83.76 0.0001
2025-08-12 2025-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 2,260,748 -9,192,557 -80.26 2,051 -60.34 0.0000
2025-05-02 2025-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 11,453,305 1,358,628 13.46 5,172 1.97 0.0001
2025-02-07 2024-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 10,094,677 174,877 1.76 5,073 -43.52 0.0001
2024-11-13 2024-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 9,919,800 360,334 3.77 8,980 -5.80 0.0002
2024-08-13 2024-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 9,559,466 1,065,071 12.54 9,534 -24.17 0.0002
2024-05-10 2024-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 8,494,395 -37,103 -0.43 12,572 35.19 0.0003
2024-02-13 2023-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 8,531,498 -756,536 -8.15 9,299 -15.15 0.0002
2023-11-13 2023-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 9,288,034 275,970 3.06 10,960 -13.76 0.0003
2023-08-11 2023-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 9,012,064 5,302,486 142.94 12,707 128.38 0.0004
2023-05-12 2023-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 3,709,578 -74,234 -1.96 5,564 25.68 0.0002
2023-02-13 2022-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 3,783,812 79,425 2.14 4,427 5.76 0.0001
2022-11-14 2022-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 3,704,387 -51,370 -1.37 4,186 -29.46 0.0001
2022-08-12 2022-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 3,755,757 -6,053,366 -61.71 5,934 -60.72 0.0002
2022-05-12 2022-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 9,809,123 -199,387 -1.99 15,106 -38.40 0.0004
2022-02-10 2021-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 10,008,510 1,456,810 17.04 24,521 13.79 0.0006
2021-11-09 2021-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 8,551,700 12,170 0.14 21,550 -11.46 0.0006
2021-08-11 2021-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 8,539,530 6,076,041 246.64 24,338 320.42 0.0007
2021-05-07 2021-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 2,463,489 862,667 53.89 5,789 105.50 0.0002
2021-02-05 2020-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,600,822 9,957 0.63 2,817 89.06 0.0001
2020-11-06 2020-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,590,865 -3,712 -0.23 1,490 7.43 0.0001
2020-08-14 2020-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,594,577 -5,732,754 -78.24 1,387 -77.14 0.0001
2020-05-01 2020-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 7,327,331 35,350 0.48 6,068 -6.50 0.0003
2020-02-13 2019-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 7,291,981 2,439 0.03 6,490 -9.14 0.0002
2019-11-08 2019-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 7,289,542 198,358 2.80 7,143 -8.42 0.0003
2019-08-22 2019-06-30 13F/A-1 BIOTIME COM 09066L105 7,091,184 -127,620 -1.77 7,800 -17.51 0.0003
2019-08-13 2019-06-30 13F BIOTIME COM 09066L105 7,091,184 -127,620 7,800
2019-05-09 2019-03-31 13F BIOTIME COM 09066L105 7,218,804 1,039,523 16.82 9,456 67.60 0.0004
2019-02-08 2018-12-31 13F BIOTIME COM 09066L105 6,179,281 76,814 1.26 5,642 -60.66 0.0003
2018-11-09 2018-09-30 13F BIOTIME COM 09066L105 6,102,467 185,876 3.14 14,340 17.65 0.0006
2018-08-09 2018-06-30 13F BIOTIME COM 09066L105 5,916,591 577,999 10.83 12,189 -15.12 0.0006
2018-05-09 2018-03-31 13F BIOTIME COM 09066L105 5,338,592 42,565 0.80 14,361 26.13 0.0007
2018-02-09 2017-12-31 13F BIOTIME COM 09066L105 5,296,027 193,039 3.78 11,386 -21.44 0.0005
2017-11-14 2017-09-30 13F BIOTIME COM 09066L105 5,102,988 65,462 1.30 14,493 -8.67 0.0007
2017-08-10 2017-06-30 13F BIOTIME COM 09066L105 5,037,526 136,228 2.78 15,868 -6.17 0.0008
2017-05-12 2017-03-31 13F BIOTIME COM 09066L105 4,901,298 4,896,379 99,540.13 16,911 93,850.00 0.0009
2017-02-10 2016-12-31 13F BIOTIME COM 09066L105 4,919 -591 -10.73 18 -14.29 0.0000
2016-11-08 2016-09-30 13F BIOTIME COM 09066L105 5,510 1,279 30.23 21 90.91 0.0000
2016-08-10 2016-06-30 13F BIOTIME COM 09066L105 4,231 882 26.34 11 10.00 0.0000
2016-05-10 2016-03-31 13F BIOTIME COM 09066L105 3,349 2,304 220.48 10 150.00 0.0000
2016-02-11 2015-12-31 13F BIOTIME COM 09066L105 1,045 0 0.00 4 33.33 0.0000
2015-11-13 2015-09-30 13F BIOTIME COM 09066L105 1,045 0 0.00 3 -25.00 0.0000
2015-08-07 2015-06-30 13F BIOTIME COM 09066L105 1,045 0 0.00 4 -20.00 0.0000
2015-05-13 2015-03-31 13F BIOTIME COM 09066L105 1,045 -293 -21.90 5 25.00 0.0000
2014-05-02 2014-03-31 13F BIOTIME COM 09066L105 1,338 0 0.00 4 -20.00 0.0000
2014-02-12 2013-12-31 13F BIOTIME COM 09066L105 1,338 0 0.00 5 0.00 0.0000
2013-11-12 2013-09-30 13F BIOTIME COM 09066L105 1,338 0 0.00 5 0.00 0.0000
2013-08-13 2013-06-30 13F BIOTIME COM 09066L105 1,338 1,338 5 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.